Voya Investment Management LLC Lowers Stake in Moderna, Inc. $MRNA

Voya Investment Management LLC decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 9.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 135,307 shares of the company’s stock after selling 14,585 shares during the quarter. Voya Investment Management LLC’s holdings in Moderna were worth $3,836,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of MRNA. S Bank Fund Management Ltd purchased a new stake in shares of Moderna in the 1st quarter valued at $25,000. SVB Wealth LLC acquired a new position in Moderna in the 1st quarter valued at about $28,000. Costello Asset Management INC purchased a new stake in Moderna during the first quarter worth about $30,000. Vega Investment Solutions acquired a new stake in shares of Moderna during the fourth quarter worth about $45,000. Finally, Sentry Investment Management LLC acquired a new stake in shares of Moderna during the first quarter worth about $31,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 0.8%

Shares of MRNA opened at $25.24 on Friday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $67.96. The firm has a market cap of $9.82 billion, a PE ratio of -3.35 and a beta of 1.93. The company’s 50 day simple moving average is $27.57 and its 200-day simple moving average is $27.99.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same period in the previous year, the business posted ($3.33) earnings per share. Moderna’s quarterly revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on MRNA shares. Barclays dropped their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a report on Monday, August 4th. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research note on Friday, August 1st. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Citigroup initiated coverage on Moderna in a research note on Friday, August 1st. They issued a “neutral” rating and a $40.00 price objective on the stock. Finally, Leerink Partners cut their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.